Literature DB >> 22566568

Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

Jennifer Schepp-Berglind1, Carl Atkinson, Michelle Elvington, Fei Qiao, Peter Mannon, Stephen Tomlinson.   

Abstract

Complement plays a key role in the pathophysiology of many inflammatory diseases, and in this study, we investigated the role of complement in the pathogenesis of inflammatory bowel disease. Compared to wild-type mice, mice deficient in C3 or factor B were protected from acute dextran sulfate sodium (DSS)-induced colitis. C1q/mannose-binding lectin (MBL) double-deficient mice, however, exhibited more severe colitis than wild-type mice. When mice were allowed to recover after DSS treatment, all C1q/MBL(-/-) mice died by day 2 of recovery period, and, surprisingly, all C3(-/-) and factor B(-/-) mice died by day 5. Serum endotoxin levels were significantly increased in complement-deficient mice prior to death, particularly in C1q/MBL(-/-) mice, and antibiotic treatment prevented the lethal effect of DSS in all complement-deficient mice. In contrast to complement deficiency, targeted complement inhibition with either complement receptor 2 (CR2)-Crry (blocks all pathways at C3 activation) or CR2-factor H (blocks alternative pathway) was highly protective at treating established acute colitis. Endotoxin levels remained low in complement-inhibited mice, and complement inhibition also reduced inflammatory cytokines, leukocyte infiltration, and tissue injury while improving wound repair and mucosal healing. CR2-factor H provided more effective protection than CR2-Crry. Thus, complement has both pathogenic and protective roles in acute DSS-induced colitis, and whereas the alternative pathway appears to play a key role in tissue inflammation and injury, the classical/lectin pathway provides important protection in terms of host defense and wound repair. Targeted inhibition of the alternative pathway may represent a therapeutic modality for treating acute phases of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566568      PMCID: PMC3370107          DOI: 10.4049/jimmunol.1200553

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  The spectrum of complement alternative pathway-mediated diseases.

Authors:  V Michael Holers
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

2.  Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease?

Authors:  Christina Hoffmann; Peter Hoffmann; Andreas Lun; Carsten Büning; Falk Hiepe; Hans U Scherer; Elisabeth Steinhagen-Thiessen; Andreas Weimann
Journal:  Immunogenetics       Date:  2010-02-25       Impact factor: 2.846

3.  Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines.

Authors:  Kay Johswich; Myriam Martin; Jessica Thalmann; Claudia Rheinheimer; Peter N Monk; Andreas Klos
Journal:  J Biol Chem       Date:  2006-10-26       Impact factor: 5.157

4.  Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5.

Authors:  Yasuyuki Deguchi; Akira Andoh; Osamu Inatomi; Yoshio Araki; Kazunori Hata; Tomoyuki Tsujikawa; Katsuyuki Kitoh; Yoshihide Fujiyama
Journal:  Int J Mol Med       Date:  2005-10       Impact factor: 4.101

5.  Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis.

Authors:  Minoru Matsuura; Kazuichi Okazaki; Akiyoshi Nishio; Hiroshi Nakase; Hiroyuki Tamaki; Kazushige Uchida; Toshiki Nishi; Masanori Asada; Kimio Kawasaki; Toshiro Fukui; Hazuki Yoshizawa; Shinya Ohashi; Satoko Inoue; Chiharu Kawanami; Hiroshi Hiai; Yasuhiko Tabata; Tsutomu Chiba
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

6.  Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.

Authors:  Carl Atkinson; Hongbin Song; Bo Lu; Fei Qiao; Tara A Burns; V Michael Holers; George C Tsokos; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

7.  Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).

Authors:  T Ueki; M Mizuno; T Uesu; T Kiso; J Nasu; T Inaba; Y Kihara; Y Matsuoka; H Okada; T Fujita; T Tsuji
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

8.  Impaired mast cell-dependent natural immunity in complement C3-deficient mice.

Authors:  A P Prodeus; X Zhou; M Maurer; S J Galli; M C Carroll
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

9.  Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice.

Authors:  Xiao-dong Peng; Xiao-hua Wu; Li-juan Chen; Zhen-ling Wang; Xiao-hong Hu; Li-fang Song; Chun-mei He; You-fu Luo; Zhi-zhi Chen; Ke Jin; Hong-gang Lin; Xiao-lei Li; Yong-sheng Wang; Yu-quan Wei
Journal:  J Pharmacol Exp Ther       Date:  2009-10-14       Impact factor: 4.030

10.  A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.

Authors:  Yuxiang Huang; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more
  15 in total

Review 1.  Deciphering microbiome and neuroactive immune gene interactions in schizophrenia.

Authors:  Emily G Severance; Robert H Yolken
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

2.  Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis.

Authors:  Lin Zou; Yan Feng; Yan Li; Ming Zhang; Chan Chen; Jiayan Cai; Yu Gong; Larry Wang; Joshua M Thurman; Xiaobo Wu; John P Atkinson; Wei Chao
Journal:  J Immunol       Date:  2013-10-23       Impact factor: 5.422

3.  Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis.

Authors:  M Elvington; J Schepp-Berglind; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

4.  Ficolin-A/2, acting as a new regulator of macrophage polarization, mediates the inflammatory response in experimental mouse colitis.

Authors:  Yi-Fei Yang; Yi-Dan Zhou; Jia-Chen Hu; Feng-Ling Luo; Yan Xie; Yan-Ying Shen; Wen-Xiu Bian; Zhi-Nan Yin; Hong-Liang Li; Xiao-Lian Zhang
Journal:  Immunology       Date:  2017-05-15       Impact factor: 7.397

5.  Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism.

Authors:  U Jain; C A Midgen; T M Woodruff; W J Schwaeble; C M Stover; A W Stadnyk
Journal:  Clin Exp Immunol       Date:  2017-01-31       Impact factor: 4.330

6.  Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Authors:  Xianzhen Hu; Stephen Tomlinson; Scott R Barnum
Journal:  Neurosci Lett       Date:  2012-10-16       Impact factor: 3.046

Review 7.  Embryonic wound healing: a primer for engineering novel therapies for tissue repair.

Authors:  Katherine E Degen; Robert G Gourdie
Journal:  Birth Defects Res C Embryo Today       Date:  2012-09

8.  Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.

Authors:  Hwei-Fang Tsai; Chien-Sheng Wu; Yi-Lin Chen; Hsiu-Jung Liao; I-Tsu Chyuan; Ping-Ning Hsu
Journal:  J Mol Med (Berl)       Date:  2015-12-02       Impact factor: 4.599

9.  A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.

Authors:  M Elvington; P Blichmann; F Qiao; M Scheiber; C Wadsworth; I Luzinov; J Lucero; A Vertegel; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 10.  Tissue-targeted complement therapeutics.

Authors:  Stephen Tomlinson; Joshua M Thurman
Journal:  Mol Immunol       Date:  2018-07-07       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.